- $113.99m
- -$290.02m
- $100.56m
- 23
- 49
- 16
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.9 | ||
| Price to Tang. Book | 0.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -42.24% | ||
| Return on Equity | -91.24% | ||
| Operating Margin | -144.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21.1 | 207.09 | 133.62 | 97.06 | 100.56 | 10.7 | 50.99 | 36.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Directors
- Tillman Gerngross CHM
- Saraswati Kenkare-mitra PRE
- Arnon Rosenthal CEO (66)
- Marc Grasso CFO (49)
- Calvin Yu VFN (45)
- Sam Jackson OTH
- Robert King OTH (57)
- Louis Lavigne LED (72)
- Elizabeth Garofalo DRC (64)
- Paula Hammond IND (57)
- Terry Mcguire IND (64)
- Richard Scheller IND (68)
- David Wehner IND (52)
- Kristine Yaffe IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 19th, 2017
- Public Since
- February 7th, 2019
- No. of Shareholders
- 5
- No. of Employees
- 238
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 99,992,600
- Address
- 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, 94080
- Web
- https://alector.com
- Phone
- +1 4152315660
- Auditors
- Ernst & Young LLP
Upcoming Events for ALEC
Alector Inc Annual Shareholders Meeting
Alector Inc Annual Shareholders Meeting
Q2 2025 Alector Inc Earnings Release
Similar to ALEC
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Alector share price?
As of Today at 19:10 UTC, shares in Alector are trading at $1.14. This share price information is delayed by 15 minutes.
How has the Alector share price performed this year?
Shares in Alector last closed at $1.14 and the price had moved by -76.3% over the past 365 days. In terms of relative price strength the Alector share price has underperformed the S&P500 Index by -78.12% over the past year.
What are the analyst and broker recommendations for Alector?
The overall consensus recommendation for Alector is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Alector dividend yield?
Alector does not currently pay a dividend.
Does Alector pay a dividend?
Alector does not currently pay a dividend.
When does Alector next pay dividends?
Alector does not currently pay a dividend.
How do I buy Alector shares?
To buy shares in Alector you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Alector?
As of the previous close price of $1.14, shares in Alector had a market capitalisation of $113.99m.
Where are Alector shares listed?
Here are the trading details for Alector:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ALEC
What kind of share is Alector?
Based on an overall assessment of its quality, value and momentum Alector is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Alector share price forecast for 2025?
The analyst consensus target price for shares in Alector is $4.58. That is 301.75% above the last closing price of $1.14.
Analysts covering Alector currently have a consensus Earnings Per Share (EPS) forecast of -$2.01 for the next financial year.
Find out moreWhat is the trend in the Alector share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alector. Over the past six months, its share price has underperformed the S&P500 Index by -74.76%.
As of the last closing price of $1.14, shares in Alector were trading -66.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Alector PE Ratio?
The Alector PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Alector?
Alector's management team is headed by:
- Tillman Gerngross - CHM
- Saraswati Kenkare-mitra - PRE
- Arnon Rosenthal - CEO
- Marc Grasso - CFO
- Calvin Yu - VFN
- Sam Jackson - OTH
- Robert King - OTH
- Louis Lavigne - LED
- Elizabeth Garofalo - DRC
- Paula Hammond - IND
- Terry Mcguire - IND
- Richard Scheller - IND
- David Wehner - IND
- Kristine Yaffe - IND